MilliporeSigma’s New BrightLab™ Cloud-hosted Software Brings IoT to R&D
- Provides scientists with cloud-based tools to improve research efficiency, processes; automates data flow
- Instrument connectivity feature allows for accessible, real-time monitoring of centralized and synched lab data
- Software addresses lab management challenges such as manual data transcription and review
MilliporeSigma today introduced its BrightLab™ cloud-based inventory management and instrument connectivity platform for research scientists. The new software includes an electronic lab notebook, which allows scientists and lab managers to track and update experiments from any computer or mobile device.
“In today’s research environment, analog methods of documentation and analysis often take us away from the research itself,” said Klaus-Reinhard Bischoff, head of Research Solutions at MilliporeSigma. “By centralizing essential research information, we are empowering scientists to be more productive, save time and avoid costly errors.”
Recognizing the increasing demand for data automation, MilliporeSigma’s BrightLab™ software connects lab instruments to the cloud via application programming interface and Internet of Things (IoT) integrations, avoiding the need for manual transcription. It saves researchers hours of unnecessary review, allowing for more time at the bench. The platform also automates workflows and produces a secure, searchable archive of reports. All information on the cloud is accessible to only to designated users since the platform is designed with SSL encryption and provides data integrity with audit trails and regular backups built in.
“As a CTO for a stem cell therapeutic company, data management is not a luxury, it’s a necessity for our clinical efficacy readiness,” said Cenk Sumen, chief technology officer, Stemson Therapeutics. “We went with (the) BrightLab™ (platform) to help us bring the lab into the 2020s and to make data management efficient, user-friendly and supportive so that the system works as your virtual assistant to remind you when your stock is running low, to help steer you to prioritizing what you need to do.”
MilliporeSigma’s BrightLab™ platform recognizes that every lab has its own devices, so it connects with a growing library of supported instruments. Once set up, scientists can search data across projects and experiments. Lab equipment maintenance reminders, calibrations and protocols are saved in one place to stay organized and, ultimately, speed up the discovery process.
The platform is available at no charge to individual lab customers in academia. For those in industry, a 30-day free trial is available on brightlab.com to test the product and gain familiarity with its core lab function optimization features.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 21,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany generated sales of €14.8 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Merck KGaA, Darmstadt, Germany, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.